| Date |
Subject |
Media |
| 2025-08-11 |
Enimmune Submits Marketing Authorization Application for EV71 Vaccine in Vietnam
|
Emerging biotech stock Enimmune announced on the 20th that its independently developed enterovirus 71 (EV71) vaccine, EnVAX-A71, has been officially submitted for marketing authorization in Vietnam. The submission was made on July 18 by its local partner, the Vietnamese state-owned company VABIOTECH, to the Drug Administration of Vietnam (DAV) under the Ministry of Health. |
| 2025-08-07 |
Collaborative Breakthrough by NCKU Cancer-Cardiology Team: New Drug Proven Effective in Preventing Cardiotoxicity from Cancer Treatments
|
The Cardiology Department, Division of Medical Oncology, and Breast Surgery Department at National Cheng Kung University Hospital (NCKU Hospital) have successfully completed the world’s first Phase II clinical trial using a next-generation heart failure drug—Angiotensin Receptor-Neprilysin Inhibitor (ARNI)—to prevent cancer therapy-related cardiac dysfunction (CTRCD). This collaborative research marks a major step forward in achieving safer and more effective integrative care for cancer patients. |
| 2025-08-07 |
Locus Cell's Order Book Extends Through End of 2025
|
Locus Cell’s large-scale CDMO facility for cell therapy in Zhubei is nearing completion and gearing up for production. The company announced yesterday (17th) that the construction of the Zhubei plant, built with an investment exceeding NT$900 million, will be completed in August this year. An additional NT$547 million will be invested in interior construction, with the goal of officially beginning production in the first quarter of next year. |
| 2025-08-06 |
HanchorBio’s HCB101 Achieves High-Dose Milestone in Clinical Development
|
HanchorBio’s novel immunotherapy drug candidate HCB101 has reached a significant milestone in its Phase I clinical trial. Three patients with advanced solid tumors received a high intravenous dose of 18 mg/kg, and no dose-limiting toxicities or serious adverse events were observed during the monitoring period, demonstrating favorable tolerability. This result was unanimously approved by the Clinical Safety Review Committee at 8:00 PM Taiwan time on July 14, laying a critical foundation for further dose escalation and broader clinical application. |
| 2025-08-06 |
EirGenix Gains Momentum from Contract Fulfillment and CDMO Growth to Boost Second-Half Performance
|
At its investor conference on the 15th, EirGenix announced positive momentum for 2024. Senior Vice President Chang Chih-Jung noted that the number of contracts signed so far this year has already surpassed that of 2023. As these contracts begin to be executed in the third and fourth quarters, along with contributions from the CDMO business, the company expects significant support for its operations in the second half of the year. |
| 2025-08-06 |
Genetics Generation Advancement Builds Smart Laboratory
|
Genetics Generation Advancement (GGA) announced yesterday (16th) that it has signed a strategic cooperation agreement with Lightest Biomedical, a subsidiary of Genomics BioSci & Tech. (GBT), to jointly establish a smart laboratory with AI scalability and compliance management capabilities. This initiative aims to accelerate the development of Lightest Biomedical’s new antibiotics and novel drugs for Parkinson’s disease, with an Investigational New Drug (IND) application to the U.S. expected by 2026. |
| 2025-08-06 |
Gongwin Biopharm's Lung Cancer Drug PTS302 Expands into Malaysia and Taiwan, Accelerating Development in the Asia-Pacific Market
|
Gongwin Biopharm (Gongwin-KY) announced yesterday (16th) that its subsidiary, Gongwin Biopharm Taiwan, has secured two key licensing deals for its lung cancer drug PTS302. |
| 2025-08-06 |
Senhwa Biosciences’ New Drug Program Sponsored by U.S. NCI: First Monotherapy Clinical Trial Begins Patient Enrollment
|
Senhwa Biosciences announced yesterday (July 16) that its investigational new drug Pidnarulex (CX-5461) has been selected for a five-year cancer treatment program sponsored by the U.S. National Cancer Institute (NCI). The first clinical trial under this program—evaluating Pidnarulex as a monotherapy for advanced solid tumors—has successfully enrolled its first patient at the NIH Clinical Center in Bethesda, Maryland, USA. The NCI will fund the clinical trial with an estimated budget of USD 4.8 million, significantly reducing Senhwa's R&D burden and accelerating drug development. |
| 2025-08-06 |
Acer’s Medical Spinoff Develops New AI Healthcare Application
|
Acer Medical, a spinoff of Acer focusing on AI in healthcare, has achieved another milestone in its AI strategy. On July 16, the company announced a partnership with Japan’s Fujitsu to co-develop a new solution named “aiGait powered by UvanceAI.” The solution utilizes Fujitsu’s high-precision AI skeletal recognition technology to analyze patients’ physical movements and gait abnormalities, helping healthcare professionals detect early signs of dementia and Parkinson’s disease, thereby improving clinical diagnosis and intervention efficiency. Acer Medical plans to roll out the solution across elderly care institutions and primary clinics in Taiwan by the end of this year. |
| 2025-08-06 |
Preventing Hospital-Acquired Infections: TYGH and NHRI Jointly Develop “Blind-Spot-Free” Hand Hygiene Monitoring System
|
Hand hygiene is a key measure in preventing infections—especially critical within hospital settings. During the COVID-19 pandemic, Taoyuan General Hospital, Ministry of Health and Welfare (TYGH), experienced a major nosocomial outbreak that led to a 42-day shutdown. In response, the hospital collaborated with the Institute of Biomedical Engineering and Nanomedicine at the National Health Research Institutes (NHRI) to develop the world’s first non-camera, de-identified hand hygiene monitoring system. This innovative system was validated in the hospital’s intensive care units (ICUs) with an accuracy rate of 70% and was featured on the cover of the international journal Global Challenges in December last year. |
